@article{8822eadd327e43c6baa3e151a7073876,
title = "Introduction: Radiation Therapy in Oligometastatic Disease",
author = "Robert Timmerman",
note = "Funding Information: This approach, although admittedly not based on published randomized phase III trials, is supported for these patients by both history and accepted standards. The option is listed third or fourth as a first line therapy by the National Comprehensive Cancer Network (NCCN) guidelines justified by lower level, but ample, evidence. Our center is an NCI Comprehensive Cancer Center and the Kidney Cancer Program is supported by one of a few NIH SPORE grants awarded in the US. We are developing new treatments for the spectrum of kidney cancer, participate in research, and validate our outcomes/results against standards. This local therapy approach in these selected patients is scrutinized regularly for both efficacy and toxicity. While no systemic therapy is used for clearly a systemic cancer, the deferral of drug therapy does not appear to come at a significant cost to patients as response and survival with salvage systemic therapy, once initiated in patients who progress, appear similar to de novo experiences with the same drugs. Again, many are cured and ultimately receive no drug therapy whatsoever. ",
year = "2021",
month = jul,
doi = "10.1016/j.semradonc.2021.03.001",
language = "English (US)",
volume = "31",
pages = "171--173",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "3",
}